

Table 12.6i
Immunosuppression Use for Antirejection Treatment from Transplant
to One Year Following Transplantation, 1998 to 2007
Recipients with Lung Transplants

	Year of Transplant									
	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007
Transplants	893	922	977	1,083	1,054	1,099	1,185	1,407	1,406	1,471
Tx with Antirejection Treatments	403	396	432	500	425	358	384	435	388	380
Antibodies										
Any in Category	15.9%	16.4%	18.8%	11.2%	13.4%	16.2%	13.8%	12.4%	12.9%	14.2%
Atgam/NRATG/NRATS	10.9%	8.3%	7.4%	4.2%	3.1%	4.7%	4.2%	4.1%	7.0%	4.5%
OKT3	3.2%	3.0%	2.5%	1.4%	1.9%	0.8%	1.0%	0.9%	0.3%	1.3%
Thymoglobulin	0.7%	5.1%	5.8%	5.8%	4.9%	5.6%	6.8%	6.7%	5.4%	6.3%
Zenapax	2.2%	1.0%	3.0%	0.8%	5.2%	7.0%	1.8%	0.5%	0.0%	0.3%
Simulect	0.2%	0.8%	2.8%	0.6%	0.2%	0.6%	0.5%	1.1%	0.3%	1.8%
Campath	0.0%	0.0%	0.0%	0.0%	0.5%	0.8%	0.5%	0.5%	0.0%	0.5%
Corticosteroids										
Any in Category	91.6%	93.2%	88.2%	92.6%	95.1%	96.1%	93.8%	94.9%	91.2%	93.2%
Steroids	91.6%	93.2%	88.2%	92.6%	95.1%	96.1%	93.8%	94.9%	91.2%	93.2%
Antimetabolites										
Any in Category	0.7%	1.5%	1.2%	1.2%	0.2%	1.4%	0.5%	1.1%	1.3%	1.1%
Cytosan	0.2%	0.8%	0.5%	0.2%	0.2%	0.6%	0.5%	0.5%	1.3%	0.5%
Methotrexate	0.5%	1.5%	0.7%	1.0%	0.0%	0.8%	0.0%	0.7%	0.0%	0.5%

Source: OPTN/SRTR Data as of May 4, 2009.

Notes:

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category.